NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $13.78 +0.04 (+0.29%) Closing price 04:00 PM EasternExtended Trading$13.75 -0.03 (-0.22%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbCellera Biologics Stock (NASDAQ:ABCL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$13.21▼$13.8850-Day Range$5.25▼$14.8252-Week Range$2.74▼$15.02Volume4.07 million shsAverage Volume6.10 million shsMarket Capitalization$4.23 billionP/E RatioN/ADividend YieldN/APrice Target$13.38Consensus RatingModerate Buy Company Overview AbCellera Biologics Inc. is a biotechnology company that develops technologies for the discovery and development of antibody medicines. Its platform combines high-throughput screening, single-cell analysis, microfluidics, data science and machine learning to identify antibodies with potential therapeutic applications. The company works with pharmaceutical and biotechnology partners worldwide, helping them discover and advance antibody candidates for areas such as cancer, infectious diseases, autoimmune disorders and other medical conditions. AbCellera provides access to its discovery platform, laboratory capabilities and scientific expertise, while also pursuing selected internal drug development programs. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera has supported antibody discovery programs for partners in multiple global markets. Its technology contributed to the discovery of bamlanivimab, an antibody treatment developed with Eli Lilly for COVID-19. Carl Hansen, one of the company’s co-founders, serves as its president and chief executive officer.AI Generated. May Contain Errors. Read More AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreABCL MarketRank™: AbCellera Biologics scored higher than 25% of companies evaluated by MarketBeat, and ranked 776th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for AbCellera Biologics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbCellera Biologics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.69) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -25.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -25.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.46% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 9.63.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 2.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.11 News SentimentAbCellera Biologics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for AbCellera Biologics this week, compared to 4 articles on an average week.Search InterestOnly 15 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABCL Stock News HeadlinesAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026October 1, 2026 | businesswire.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 1, 2026 | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)JPMorgan Chase & Co. Begins Coverage on AbCellera Biologics (NASDAQ:ABCL)October 1, 2026 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week High - What's Next?September 30, 2026 | americanbankingnews.comAbcellera Biologics (ABCL)September 29, 2026 | es.investing.comWhy did IOVA, ABCL, CRWD stocks surge to 52-week highs today?September 29, 2026 | msn.comJPMorgan Initiates AbCellera Biologics at Overweight With $17 Price TargetSeptember 29, 2026 | marketscreener.comMSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $3.42 at the beginning of the year. Since then, ABCL shares have increased by 299.3% and is now trading at $13.6550. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. The company earned $4.05 million during the quarter, compared to analyst estimates of $7.85 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 17.49% and a negative net margin of 248.83%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $423 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,150,000 shares at $17.00-$18.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today10/05/2026Next Earnings (Confirmed)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ABCL's financial health is in the Green zone, according to TradeSmith. ABCL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees562Year Founded2012Price Target and Rating Average Price Target for AbCellera Biologics$13.38 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside-2.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.41 million Net Margins-248.83% Pretax Margin-297.36% Return on Equity-17.49% Return on Assets-12.36% Debt Debt-to-Equity RatioN/A Current Ratio12.77 Quick Ratio12.77 Sales & Book Value Annual Sales$75.13 million Price / Sales56.24 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book4.27Miscellaneous Outstanding Shares306,610,000Free Float219,533,000Market Cap$4.23 billion OptionableOptionable Beta1.41 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ABCL) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts